Raymond James Financial Services Advisors Inc. Has $36.58 Million Holdings in Boston Scientific Co. (NYSE:BSX)

Raymond James Financial Services Advisors Inc. boosted its stake in Boston Scientific Co. (NYSE:BSX - Free Report) by 5.2% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 534,016 shares of the medical equipment provider's stock after buying an additional 26,466 shares during the quarter. Raymond James Financial Services Advisors Inc.'s holdings in Boston Scientific were worth $36,575,000 at the end of the most recent quarter.

Several other institutional investors have also bought and sold shares of the stock. PFG Investments LLC boosted its stake in Boston Scientific by 61.3% in the 1st quarter. PFG Investments LLC now owns 7,885 shares of the medical equipment provider's stock valued at $540,000 after buying an additional 2,997 shares in the last quarter. Altfest L J & Co. Inc. boosted its stake in Boston Scientific by 50.1% in the 1st quarter. Altfest L J & Co. Inc. now owns 9,720 shares of the medical equipment provider's stock valued at $666,000 after buying an additional 3,243 shares in the last quarter. Maryland State Retirement & Pension System boosted its stake in Boston Scientific by 0.9% in the 1st quarter. Maryland State Retirement & Pension System now owns 114,841 shares of the medical equipment provider's stock valued at $7,762,000 after buying an additional 973 shares in the last quarter. Accel Wealth Management acquired a new stake in Boston Scientific in the 1st quarter valued at $218,000. Finally, First Trust Direct Indexing L.P. boosted its stake in Boston Scientific by 9.9% in the 1st quarter. First Trust Direct Indexing L.P. now owns 38,506 shares of the medical equipment provider's stock valued at $2,637,000 after buying an additional 3,482 shares in the last quarter. Institutional investors and hedge funds own 89.07% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on BSX shares. Barclays lifted their price objective on Boston Scientific from $70.00 to $78.00 and gave the company an "overweight" rating in a research report on Friday, April 26th. JPMorgan Chase & Co. lifted their price objective on Boston Scientific from $72.00 to $82.00 and gave the company an "overweight" rating in a research report on Thursday, April 25th. Citigroup lifted their price objective on Boston Scientific from $79.00 to $85.00 and gave the company a "buy" rating in a research report on Thursday, April 25th. Royal Bank of Canada lifted their price objective on Boston Scientific from $78.00 to $82.00 and gave the company an "outperform" rating in a research report on Thursday, April 25th. Finally, Evercore ISI lifted their price objective on Boston Scientific from $72.00 to $78.00 and gave the company an "outperform" rating in a research report on Thursday, April 25th. Three research analysts have rated the stock with a hold rating, eighteen have issued a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $75.09.

Boston Scientific Stock Down 0.2 %

BSX stock traded down $0.18 during mid-day trading on Thursday, reaching $72.03. The company had a trading volume of 6,487,184 shares, compared to its average volume of 6,652,362. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.32 and a quick ratio of 0.82. The stock has a 50 day simple moving average of $68.30 and a two-hundred day simple moving average of $61.11. The company has a market capitalization of $108.05 billion, a price-to-earnings ratio of 60.53, a PEG ratio of 2.47 and a beta of 0.77. Boston Scientific Co. has a 52 week low of $48.35 and a 52 week high of $74.39.

Boston Scientific (NYSE:BSX - Get Free Report) last posted its quarterly earnings results on Wednesday, January 31st. The medical equipment provider reported $0.55 earnings per share for the quarter, beating analysts' consensus estimates of $0.51 by $0.04. The firm had revenue of $3.73 billion during the quarter, compared to the consensus estimate of $3.59 billion. Boston Scientific had a return on equity of 16.63% and a net margin of 12.06%. During the same period last year, the company earned $0.45 earnings per share. As a group, equities analysts predict that Boston Scientific Co. will post 2.32 earnings per share for the current fiscal year.

Insider Activity

In other news, EVP John Bradley Sorenson sold 17,587 shares of the firm's stock in a transaction that occurred on Wednesday, May 1st. The stock was sold at an average price of $71.50, for a total value of $1,257,470.50. Following the completion of the sale, the executive vice president now directly owns 50,638 shares of the company's stock, valued at $3,620,617. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. In other news, EVP John Bradley Sorenson sold 17,587 shares of the firm's stock in a transaction that occurred on Wednesday, May 1st. The stock was sold at an average price of $71.50, for a total value of $1,257,470.50. Following the completion of the sale, the executive vice president now directly owns 50,638 shares of the company's stock, valued at $3,620,617. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Wendy Carruthers sold 6,983 shares of the firm's stock in a transaction that occurred on Friday, February 23rd. The shares were sold at an average price of $66.89, for a total value of $467,092.87. Following the completion of the sale, the executive vice president now directly owns 56,508 shares of the company's stock, valued at $3,779,820.12. The disclosure for this sale can be found here. Insiders sold a total of 78,384 shares of company stock valued at $5,395,560 over the last three months. Insiders own 0.50% of the company's stock.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.

Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Co. (NYSE:BSX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.